Claudine Isaacs

Claudine Isaacs

Auto-generated profile, based on publicly available information

Claudine Isaacs

Lombardi Comprehensive Cancer Center Georgetown University Washington District of Columbia USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Cancer Cell
Verified
Journal Article
Closed access
LPLajos Pusztai
Lajos Pusztai
CYChristina Yau
Christina Yau
DWDenise M. Wolf
Denise M. Wolf
HHHyo S. Han
Hyo S. Han
LDLili Du
Lili Du
LELaura J. Esserman
Laura J. Esserman

4 January 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
RCRikki A Cannioto
Rikki A Cannioto
AHAlan Hutson
Alan Hutson
SDShruti Dighe
Shruti Dighe
WMWilliam McCann
William McCann
SMSusan McCann
Susan McCann
CAChristine Ambrosone
Christine Ambrosone
Background: Although physical activity has been consistently associated with reduced breast cancer mortality, evidence is largely based on data collected at one occasion. We examined how pre- and postdiagnosis physical activity was associated with survival outcomes in high-risk breast cancer patients. Methods: Included were 1340 patients enrolled in the Diet, Exercise, Lifestyle and Cancer Prognosis (DELCaP) Study, a prospective study of lifestyle and prognosis ancillary to a SWOG clinical trial (S0221). Activity before diagnosis, during treatment, and at 1- and 2-year intervals after enrollment was collected. Patients were categorized according to the Physical Activity Guidelines for Americans as meeting the minimum guidelines (yes/no) and incrementally as inactive, low active, moderately active (meeting the guidelines), or high active. Results: In joint-exposure analyses, patients meeting the guidelines before and 1 year after diagnosis experienced statistically significant reductions in hazards of recurrence (hazard ratio [HR] = 0.59, 95% confidence interval [CI] = 0.42 to 0.82) and mortality (HR = 0.51, 95% CI = 0.34–0.77); associations were stronger at 2-year follow-up for recurrence (HR = 0.45, 95% CI = 0.31 to 0.65) and mortality (HR = 0.32, 95% CI = 0.19 to 0.52). In time-dependent analyses, factoring in activity from all time points, we observed striking associations with mortality for low- (HR = 0.41, 95% CI = 0.24 to 0.68), moderate- (HR = 0.42, 95% CI = 0.23 to 0.76), and high-active patients (HR = 0.31, 95% CI = 0.18 to 0.53). Conclusions: Meeting the minimum guidelines for physical activity both before diagnosis and after treatment appears to be associated with statistically significantly reduced hazards of recurrence and mortality among breast cancer patients. When considering activity from all time points, including during treatment, lower volumes of regular activity were associated with similar overall survival advantages as meeting and exceeding the guidelines.

15 March 2011 in Breast Disease
Verified
Journal Article
Closed access
PDF file
BPBeth N Peshkin
Beth N Peshkin
MAMichelle L Alabek
Michelle L Alabek
CIClaudine Isaacs
Claudine Isaacs
Identifying breast cancer patients at increased risk for carrying a mutation in the BRCA1 and BRCA2 genes is an important objective in clinical practice. Although age at diagnosis, family history of breast and/or ovarian cancer, and ethnicity are all

5 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAmy S. Clark
Amy S. Clark
CYChristina Yau
Christina Yau
DWDenise M. Wolf
Denise M. Wolf
EPEmanuel F. Petricoin
Emanuel F. Petricoin
LVLaura J. van ‘t Veer
Laura J. van ‘t Veer
ADAngela M. DeMichele
Angela M. DeMichele
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ado-trastuzumab emtansine plus pertuzumab (T-DM1/P) and paclitaxel, trastuzumab and pertuzumab (THP). Eligible women have >2.5 cm clinical stage II/III HER2+breast cancer, adaptively randomized to T-DM1/P, THP, or a common control arm of paclitaxel/trastuzumab (TH), followed by doxorubicin/cyclophosphamide, then surgery. Both T-DM1/P and THP arms ‘graduate’ in all subtypes: predicted pCR rates are 63%, 72% and 33% for T-DM1/P (n = 52), THP (n = 45) and TH (n = 31) respectively. Toxicity burden is similar between arms. Degree of HER2 pathway signaling and phosphorylation in pretreatment biopsy specimens are associated with response to both T-DM1/P and THP and can further identify highly responsive HER2+tumors to HER2-directed therapy. This may help identify patients who can safely de-escalate cytotoxic chemotherapy without compromising excellent outcome.

3 October 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
BTBrandie C. Taylor
Brandie C. Taylor
XSXiaopeng Sun
Xiaopeng Sun
PGPaula I. Gonzalez-Ericsson
Paula I. Gonzalez-Ericsson
VSVioleta Sanchez
Violeta Sanchez
MSMelinda E. Sanders
Melinda E. Sanders
JBJustin M. Balko
Justin M. Balko
Despite the success of immune checkpoint inhibition (ICI) in treating cancer, patients with triple-negative breast cancer (TNBC) often develop resistance to therapy, and the underlying mechanisms are unclear. MHC-I expression is essential for antigen presentation and T-cell–directed immunotherapy responses. This study demonstrates that TNBC patients display intratumor heterogeneity in regional MHC-I expression. In murine models, loss of MHC-I negates antitumor immunity and ICI response, whereas intratumor MHC-I heterogeneity leads to increased infiltration of natural killer (NK) cells in an IFNγ-dependent manner. Using spatial technologies, MHC-I heterogeneity is associated with clinical resistance to anti-programmed death (PD) L1 therapy and increased NK:T-cell ratios in human breast tumors. MHC-I heterogeneous tumors require NKG2A to suppress NK-cell function. Combining anti-NKG2A and anti–PD-L1 therapies restores complete response in heterogeneous MHC-I murine models, dependent on the presence of activated, tumor-infiltrating NK and CD8+ T cells. These results suggest that similar strategies may enhance patient benefit in clinical trials. Significance: Clinical resistance to immunotherapy is common in breast cancer, and many patients will likely require combination therapy to maximize immunotherapeutic benefit. This study demonstrates that heterogeneous MHC-I expression drives resistance to anti–PD-L1 therapy and exposes NKG2A on NK cells as a target to overcome resistance. This article is featured in Selected Articles from This Issue, p. 201

1 January 2002 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CIClaudine Isaacs
Claudine Isaacs
BPBeth N. Peshkin
Beth N. Peshkin
MSMarc Schwartz
Marc Schwartz
TDTiffani A. DeMarco
Tiffani A. DeMarco
DMDavid Main
David Main
CLCaryn Lerman
Caryn Lerman